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Soft tissue sarcomas (STS) are a rare, heterogeneous and complex group of 
tumors of mesenchymal origin. A great proportion of patients (pts) with high-risk 
STS eventually develop metastatic disease, and pts with advanced disease have a 
median overall survival (OS) of about 12 months [Judson I et al, Lancet Oncol 
2014]. STS have a tendency to metastasize to lungs, but may also relapse in other 
distant organs. Systemic chemotherapy (CT) comprising anthracycline therapy 
remains to date the standard reference regimen.  
Among the over 50 different histological types known, leiomyosarcoma (LMS),  
undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) 
contain complex genomes characterized by a multitude of rearrangements, 
amplifications, and deletions.  Only few diagnostic and prognostic markers exist, 
and the accurate diagnosis and prediction of the clinical behaviour of many of 
these tumors remain a challenge.  Some biomarkers, specifically markers related 
to Epithelial to Mesenchymal transition (EMT) and its reverse process (MET) and 
microRNAs (miRNAs) may be useful to identify a possible signature with 
prognostic and diagnostic value, and could also elucidate new possible pathogenic 
mechanisms. The aims of this study were to describe efficacy and toxicity of CT 
for advanced STS in a cohort of unselected pts treated at Istituto Oncologico 
Veneto (IOV), and to evaluate the significance and the prognostic value of the 
expression of markers linked to EMT/MET processes, related miRNAs and myo-
miRNAs in tumors samples. 
 
Patients and methods: 
Medical records of pts with advanced STS treated at Istituto Oncologico Veneto 
from January 2010 to December 2015 were reviewed and clinical data retrieved. 
Vital status was recorded as of September 30th 2016. OS was estimated with 
Kaplan-Meier method, and univariate analysis for OS was performed with Cox 
regression.  
Tumor tissues from pts affected by STS referred to the Istituto Oncologico 
Veneto, Padova, were either retrieved from the Tissue Biobank of the Department 




or freshly received as tru-cut biopsy or surgical specimen. All the specimens were 
reviewed by an expert pathologist for confirmation of representativeness of the 
samples. Samples were collected from November 2014 (date of Ethical Approval) 
to September 2016.  Eligible histological types were LMS, UPS, and MFS.  
Total RNA, enriched in low molecular weight molecules, was extracted using 
NucleoSpin miRNA columns (MN GmbH & Co, Germany) from frozen or fresh  
tissue samples.  
Markers linked to EMT/MET were analyzed by qRT-PCR using primers specific 
for epithelial markers (E-cadherin and ZO-1), and mesenchymal markers (Snail, 
Slug, Vimentin, Zeb−1, Zeb−2, and N-cadherin).  Expression of alpha-SMA was 
also evaluated along with Periostin. The expression of specific miRNAs linked to 
EMT (miR-100-5p-5p), to MET (miR200b-3p, miR30b-5p and miR30c-5p) and 
myo-miRNAs (miR1, miR133a-3p andmiR133b) was measured. The study was 
approved by the institutional Ethics Committee and conducted in accordance with 
the Helsinki Declaration and Good Clinical Practice guidelines. Written informed 
consent was obtained from all pts. 
 
Results: 
Clinical evaluation of pts referred to Medical Oncology Unit 1 – Istituto 
Oncologico Veneto, IOV -  IRCCS. 
Overall 405 pts were eligible, of whom 51.4% had advanced or metastatic disease.  
One hundred-sixty seven patients were taken in charge at Istituto Oncologico 
Veneto. Median age was 61 years (range 16-89); 87 patients (52.1%) were female, 
and 54 (32.3%) were aged ≥ 70 years.  Out of these, 37 patients (19.8%) did not 
receive chemotherapy.  The prevalent histological types were LPS (24%), LMS 
(19.8%) and UPS (11.4%). Most pts had ECOG PS 0-1 (71.8%).  Globally, 
median OS was 17.7 months (95%CI 13.59-21.75) and median PFS was 10 
months (95%CI  7.9-12.0).  Patients receiving only first-line CT were 57 (34.1%); 
43 patients (25.7%) received more than two lines of CT.  First-line CT regimens 
were anthracycline-based in 81 patients (62.3%).  
Median OS of patients treated with CT was 19.9 months (95%CI 16.4–23.5), 
while that of untreated patients was 3.3 months (95%CI 1.3-5.2), p<0.001. At 
univariate analysis ECOG PS, anemia and lymphopenia  were associated with 




and PS 2-3, respectively 23.5 months (95%CI  18.5–28.5), 15.8 months (95%CI 
18.5–28.5), 6.6 months (95%CI 1.0-12.3), p<0,001.  Baseline low lymphocyte 
count was associated with worse survival, with median OS of12.5 months (95%CI 
5.4-19.5) compared to patients with neutrophil/lymphocyte ratio <3, who had 
median OS of 22.8 months (95%CI 15.2-30.4), p=0.005.  Baseline anemia was 
also associated with worse survival, with median OS for anemic patients (Hb<12 
g/dL) being 9 months (95%CI 3.2-14.8) and median OS for non-anemic patients 
being 20.9 months (95%CI 16.6-25.4).  No difference in OS was seen according 
to age, gender, chemotherapy regimen, BMI, albumin levels, or LDH levels.  
Grade ≥3 toxicities occurred in 59 patients (45.4%), and 23 patients (17.7%) 
required hospitalization for toxicity management.  
 
Molecular analysis on samples 
Overall, 55 STS samples were fully characterized, specifically 28 LMS, of which 
10 low/intermediate grade (LG) and 18 high grade (HG) LMS; 13 myxoid 
sarcomas (of which 8 MFS/ and 5 low-grade FMS); and 14 UPS.  
Correlation of EMT-related markers and miRNA with  histological type and grade 
was assessed. The samples were analysed for the expression of E-cadherin and 
ZO-1, as epithelial markers, and of Slug, Vimentin, Snail, ZEB-1, ZEB-2, N-
cadherin, and Periostin, as markers related to a mesenchymal status. E-cadherin 
expression was not found in all analysed STS. 
Alpha-SMA was significantly expressed in LMS compared to UPS and MFS/FMS 
(p<0.001), and not significantly different in UPS compared to MFS/FMS. ZEB-1 
and ZEB-2 expression was significantly higher in LMS compared to MFS/FMS 
(p<0.001) and UPS (p=0.001 for ZEB-1, p=0.003 for ZEB-2), whereas no 
differential expression was measured between UPS and MFS/FMS. Interestingly, 
ZEB-1 and ZEB-2 were differentially expressed in HG and LG LMS (p=0.038 for 
ZEB-1, p=0.048 for ZEB-2). Also N-cadherin expression was significantly higher 
in LMS compared to MFS/FMS (p=0.006) and UPS (p=0.028), whereas no 
differential  expression was measured according to the grading.   
As for periostin, this was found to be higher in LMS compared to MFS/SFM 
(p=0.002), and in UPS compared to MFS/FMS (p=0.005); no difference was 
observed between LMS and UPS. 




significantly higher in LMS compared to MFS and UPS (p=0.002), though no 
difference was observed between HG and LG LMS. All other analysed miRNAs 
did not show a different expression in the three histological subtypes, nor it was 
different according to grade., with the exception of miR-100-5p, which was found 
to be significantly over-expressed in LMS compared to MFS/FMS (p=0.02). An 
inverse correlation between Slug and myo-miRNAs expression was observed. 
Also, a direct correlation between ZEB family members, and an inverse 
correlation between ZEB-1 and miR-200b was observed.  
In univariate analysis, high ZEB-1 (≥0.4) was correlated with worse OS (2.3 
months, 95%CI 0.9-3.4) vs low ZEB-1 (8.6 months, 1.5 – n.r.), p=0.058. 
Similarly, high ZEB-2 (≥0.9) was correlated with worse OS (2.2 months, 95%CI 
0.9-32.7) vs low ZEB-2 (8.6 months, 95%CI 1.5 – n.r.), p=0.052. High Periostin 
was also correlated with worse OS (2.2 months, 95%CI 1.2-2.5) vs low Periostin 
(8.6 months, 95%CI 1.3 – n.r.), p=0.028.  In multivariate analysis, grade and 
periostin and ZEB-1 levels confirmed to be associated with overall survival.  
All the other analysed EMT-related markers, as well as all analysed miRNAs, 
were not correlated with OS nor with PFS. 
 
Conclusions: 
Our clinical data confirm that there is a benefit for pts that have been treated for 
advanced disease compared to those not receiving active treatment. There remains 
a need for novel effective therapies in metastatic STS, particularly for pts with 
certain chemo-resistant subtypes. 
The analysis on tumor samples highlighted that a “myo-miRNA” signature  may 
serve as potential confirmatory markers in LMS samples with 
difficult/controversial histological findings Moreover, some biomarkers linked to 
the mesenchymal phenotype  (i.e. ZEB-1, ZEB-2, and Periostin) may have 
prognostic value. 
In light of the findings from this study, we have planned to proceed with 
validation of such results in a larger sample and to provide a correlation with 
immunoistochemical staining.  
Also, we are planning to  verify whether circulating Periostin and N-cadherin may 







1.1 Epidemiology and Classification of Soft Tissue Sarcomas 
 High-grade soft tissue sarcomas (STS) are a heterogeneous and complex group of 
tumors of mesenchymal origin that account for approximately 1% of all adult 
malignancies [Fletcher CDM et al, WHO Classification of tumours of soft tissue 
and bone 2013; Siegel RL et al, CA Cancer J Clin 2016].  
The incidence is estimated to be 4-5 new cases/100.000 persons/year [AIOM-
AIRTUM I Numeri del cancro 2016; Jemal A et al, CA Cancer J Clin 2007].  
There are about 12,310 new cases of soft tissue sarcoma diagnosed each year in 
the United States, with 4,990 deaths [Siegel RL et al, CA Cancer J Clin 2016]. 
Taking into account the overall population, the figures are similar in Italy, where 
in 2016 it is estimated that 2,100 new cases will be diagnosed, 1,200 in men and 
900 in women [AIOM-AIRTUM I Numeri del cancro 2016].  
Still, the true incidence of STS remains uncertain to some degree, since issues 
such as underreporting as well as the changing of classification over time are 
common. 
The overall estimated 5-year survival rate is 65.3% in the US, and the 5-year 
survival is 18.4% in patients with sarcomas with distant spread [NCI SEER Stat 
Fact Sheets: Soft Tissue Including Heart Cancer, 2016]. STS account for 1% of 
deaths due to cancer in both sexes [AIOM LG 2015], with 5-year survival rates in 
Italy ranging from 61 to 70% (Table 1).  
Indeed, a great proportion of patients with high-risk STS eventually develop 
metastatic disease, and patients with advanced disease have a median overall 
survival (OS) of about 12 months [Judson I et al, Lancet Oncol 2014]. In 
particular, high-grade sarcomas show high rates of local recurrence, frequent 
metastases, and poor prognosis [Zagars CK et al., Cancer 2003]. 
 
Table 1.  Relative 5-year standardized survival (%) after diagnosis of soft tissue 
sarcoma, according to geographic area in Italy  (years considered 2000-2004, 
AIRTUM pool) [AIRTUM WG. Epidemiol Prev 2011; 26 (5-6): Suppl. 1] 
 
	   Male	   	   Female	  North-­‐west	   North-­‐east	   Center	   South	   North-­‐west	   North-­‐east	   Center	   South	  




Approximately 80% of sarcomas originate from soft tissue, and the rest originates 
from bone.  
STS may develop in any part of the body, yet most originate in extremities and in 
girdles (70%), 10% in the trunk, 10% in the retroperitoneum, 5% in viscera and 
the remaining 5% in the head and neck region [AIOM, LG 2015].  
The histopathologic spectrum of sarcomas is broad, presumably because the 
embryonic mesenchymal cells from which they arise have the ability to mature 
into several types of connective tissues, such as striated skeletal and smooth 
muscle, adipose and fibrous tissue, bone, and cartilage. Although ectodermal in 
origin, malignant tumors affecting peripheral nerves are included because of 
similarities in their clinical behaviour, management, and outcome.  
As classified by the World Health Organization (WHO), the group of STS 
includes more than 80 different histologic subtypes [Fletcher CDM et al, WHO 
Classification 2013]. The WHO classifies most soft tissue sarcomas according to 
the presumptive tissue of origin, that is the normal tissues which the tumor most 
closely resembles [Siegel RL et al, CA Cancer J Clin 2016]. Examples include 
liposarcoma (LPS), synovial sarcoma (SS), leiomyosarcoma (LMS), 
rhabdomyosarcoma (RMS), fibrosarcoma, and angiosarcoma. In some cases, 
histogenesis is uncertain and the designation reflects the morphologic appearance 
of the cells or the architectural pattern (eg, alveolar sarcoma of soft parts, 
epithelioid sarcoma, clear cell sarcoma, Ewing sarcoma). 
The most common subtypes of soft tissue sarcoma in adults are undifferentiated 
pleomorphic sarcoma – UPS - (previously called malignant fibrous histiocytoma), 
LPS, and LMS [Wibmer C et al, Ann Oncol. 2010; Toro JR et al, Int J Cancer 
2006].  
Only few diagnostic and prognostic markers exist, and the cellular origin of 
several sarcoma subtypes is unknown. Therefore, the accurate diagnosis and the 
prediction of the clinical behaviour of many of these tumors remain a challenge 
[van de Rijn M and Fletcher JA, Annu Rev Pathol 2006].  
 
1.2 Diagnosis 
When a soft tissue mass is present, and a STS is suspected, ultrasound is often 
carried out as first imaging approach, yet magnetic resonance imaging (MRI) is 




well in retroperitoneal tumours, and it is also useful for staging purposes.  
After proper imaging assessment, diagnosis must be ascertained by means of core 
needle biopsy, possibly by using ≥14 Gauge needles. An excisional biopsy can be 
performed for superficial lesions less than 3 cm in size. In selected cases, after 
multidisciplinary discussion, an open biopsy may be needed to complete or 
confirm diagnosis.   
Imaging may also provide  information that helps to estimate the malignancy 
grade (i.e. necrosis) for patients who are candidate for neoadjuvant treatment, in 
those cases in which assignment of grade on bioptic specimen is difficult. Biopsy 
should be planned in such a way that the pathway and the scar can be removed by 
definitive surgery. Histological diagnosis should be made according to the 2013 
WHO classification [Fletcher CDM et al, WHO 2013]. A pathological expert 
validation is required in all cases when the original diagnosis was made outside a 
reference centre/network [Ray-Coquard I et al, Ann Oncol 2012].  
Pathological diagnosis relies on morphology and immunohistochemistry. It should 
be complemented by molecular pathology, especially when the specific 
histological diagnosis is doubtful, and/or the clinical pathological presentation is 
unusual; it may also have prognostic and/or predictive relevance.  
The malignancy grade should be provided in all cases in which this is feasible 
based on available systems, because it has prognostic and predictive meaning. The 
‘Federation Nationale des Centres de Lutte Contre le Cancer’ (FNCLCC) grading 
system is generally used, which distinguishes three malignancy grades based on 
differentiation, necrosis and mitotic rate [Trojani M et al, Int J Cancer 1984]. 
Whenever possible, the mitotic rate should be provided independently. An effort 
should be made to improve the reliability of mitotic count as actually recorded. 
Grading cannot be assigned after preoperative medical treatment, by which the 
tumour tissue undergoes major therapy-related changes. 
Tumour site should be properly recorded. Tumour size and tumour depth in 
relation to the superficial fascia should also be recorded, since they display a 
prognostic value..  
If preoperative treatment is carried out, the pathology report should include an 
assessment of the histological response of the tumour.  
For STS no validated system is available at present to guide pathological response 




specific prognostic significance, as it happens for osteosarcoma and Ewing 
sarcoma.  
STS can arise in every body anatomic district, and a multidisciplinary approach is 
mandatory in all cases, involving pathologists, radiologists, surgeons, radiation 
therapists, medical oncologists, nuclear medicine specialists, and organ-based 
specialists, as needed. Management should be carried out in reference centres for 
sarcomas and/or within reference networks sharing multidisciplinary expertise. 
Such a centralised referral should be pursued as soon as a clinical sarcoma 
diagnosis is suspected.  
This translates in the recommendation of referring all patients having a deep soft 
tissue mass, or presenting with a superficial lesion of soft tissues having a 
diameter of >5 cm [ESMO, Ann Oncol 2014].  
 
1.3 Stage classification and risk assessment  
In STS the common staging classification adopted is the American Joint 
Committee on Cancer (AJCC)/International Union against Cancer (UICC) stage 
classification system [Edge SB et al, AJCC Cancer Staging Manual, 2010]. 
Such a classification has indeed limited relevance and should be improved.  It 
stresses the importance of the malignancy grade in sarcoma, along with tumour 
size and tumour depth for limb sarcomas.  
Site, tumour resectability and presence of metastases are also important.  
For staging purposes, a chest spiral CT scan is mandatory. Regional lymph node 
metastases are infrequent, with the exception of some histological types, such as 
epithelioid sarcoma and clear cell sarcoma, for which regional assessment through 
CT/MRI may be added to the usual staging procedures. Abdomen assessment by 
means of CT scan is suggested, in particular for some histotypes such as limb 
myxoid liposarcoma. A brain CT scan may be added for alveolar soft part 
sarcoma, clear cell sarcoma and angiosarcoma. 
Other imaging techniques, such as bone scan, whole-body MRI or PET scan, are 









1.4 Treatment  
Treatment options for STS include surgery, radiotherapy, and systemic anticancer 
therapy (cytotoxic chemotherapy or targeted cancer agents). Surgery and radiation 
therapy are the standard initial treatment options for patients with primary 
resectable STS; however, up to 50% of patients experience recurrence 
[Wesolowski R et al, Cleve Clin J Med 2010]. Neoadjuvant and/or adjuvant 
chemotherapy with the combination of an anthracycline (either doxorubicin or 
epirubicin) and ifosfamide has been shown to improve disease-free survival 
(DFS), yet with only marginal improvement in overall survival (OS), at the price 
of high toxicity, therefore a clear indication to (neo)adjuvant treatment is still 
debated [Pervaiz N et al, Cancer 2008; Gronchi A et al,  Ann Oncol 2016]. 
For patients with advanced unresectable or metastatic STS, chemotherapy is the 
mainstay of treatment. First-line regimens for metastatic STS in most cases 
include anthracyclines, alone or in combination with other agents, as 
recommended by the National Comprehensive Cancer Network [NCCN 
guidelines “Soft Tissue Sarcoma”, version 2.2016] and the European Society of 
Medical Oncology [ESMO, Ann Oncol 2014], although first-line treatment 
recommendations may vary by histologic subtype and previous treatment. Other 
cytotoxic chemotherapy agents that have shown activity in clinical trials are 
gemcitabine, docetaxel, vinorelbine, pegylated liposomal doxorubicin, 
temozolomide, trabectedin and eribulin. All these agents can be associated with 
significant adverse events, including pancytopenia, febrile neutropenia, nausea, 
alopecia, and fatigue. The two most recently approved cytotoxic drugs are 
Trabectedin and Eribulin.   
Trabectedin is a tetrahydroisoquinoline alkaloid derived from the Caribbean 
marine tunicate Ecteinascidia turbinate, which has been approved for treatment of 
patients with advanced STS after failure of anthracycline and ifosfamide or in 
patients with advanced STS for whom these agents are not suitable [Demetri G et 
al,  J Clin Oncol 2016]. Trabectedin has shown a particularly important activity in 
the treatment of mixoid round cell LPS [Grosso F et al, Ann Oncol 2009] and in 
general in translocation-related sarcomas [Kawai A et al, Lancet Oncol 2015]. Its 
antineoplastic activity depends on several mechanisms, including a drug-induced 




recombination (e.g., cells with mutations of BRCA1/2), an immunomodulatory 
effect, with selective cytotoxicity against monocytes and tumor-associated 
macrophages, and a regulation of various transcription factors involved in cell 
proliferation [D’Incalci M. Future Oncol 2013].  
Eribulin, a microtubule-dynamics inhibitor which is a structurally modified 
analogue of halichondrin B originally isolated from the marine sponge 
Halichondria okadai, has been recently shown to be active in STS. A randomized 
phase III trial of Eribulin compared to Dacarbazine in advanced STS 
demonstrated significant improvement in overall survival in patients treated with 
Eribulin compared to- those assigned to dacarbazine (median 13.5 vs 11.5 months 
[9.6–13.0]; HR 0.77 [95% CI 0.62–0.95]; p=0.0169) [Schöffski P et al, Lancet 
2016]. Benefit with Eribulin seemed greater in patients with LPS, and in light of 
this finding Eribulin has been approved by FDA for the treatment of metastatic 
LPS in 2016.  
Moreover, a number of targeted cancer agents, including sunitinib and pazopanib, 
have demonstrated activity in particular STS histologic subtypes. Sunitinib, a 
multityrosine kinase inhibitor of vascular endothelial growth factor receptor- 
(VEGFR-) 2, platelet-derived growth factor receptor- (PDGFR-) β, and c-Kit, 
showed activity in patients with locally advanced or metastatic STS in a non-
randomized phase II trial [George S et al, J Clin Oncol 2009]. Pazopanib is a 
multityrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, 
PDGFR-β, and c-Kit, which has been approved for use as single agent in patients 
with advanced STS who have received prior chemotherapy [van der Graaf WT et 
al, Lancet 2012].  
Recently Olaratumab, a human anti-platelet-derived growth factor receptor-α 
(PDGFR-α) monoclonal antibody, has been demonstrated to improve both PFS 
and OS in association with doxorubicin, compared to doxorubicin alone, in 
patients with advanced or metastatic soft-tissue sarcoma in a phase II randomized 
trial [Tap WD et al. Lancet. 2016], and a phase III trial is currently ongoing.  
 
1.5 Clinical and molecular markers in STS 
1.5.1  Clinical markers  
To date, histological grade, location and size are universally established risk 




greater than 5 cm are considered as adverse prognostic factors. 
In addition, some circulating markers such as C-reactive protein, haemoglobin, 
serum albumin, neutrophils to lymphocyte ratio have been demonstrated to carry a 
prognostic significance with regard to survival in different types of carcinomas  
[Al Murri AM et al, Br J Cancer. 2006; Li MX et al, Int J Cancer. 2014; Hu K et 
al, BMJ Open. 2015] 
Only a few studies have investigated the prognostic value of serum biomarkers in 
bone sarcoma [Aggerholm-Pedersen N et al, Transl Oncol. 2016], and STS 
[Nakamura T et al, Cancer. 2012].  
A prognostic clinical score suggested by the Royal Marsden Hospital (London, 
UK) (“RMH score”) able to estimate prognosis for patients enrolled in phase I 
trials was recently validated in patients with bone sarcomas enrolled in phase I 
trials at the MD Anderson Cancer Center (Houston, USA).  In this study, 
independent factors that predicted shorter survival were male sex, more than two  
metastatic sites, more than three previous therapies, hemoglobin level <10.5 g/dL, 
platelet count >200 x103/L, creatinine level ≥1.3 mg/dL, and lactate 
dehydrogenase level (LDH) > Upper Level of Normal (ULN) [Livingston JA et 
al, Oncotarget. 2016].  
In a retrospective study conducted at the Royal Marsden Hospital on older 
patients treated with palliative chemotherapy for metastatic STS low lymphocyte 
count, low albumin, anemia, along with histological subtype ad presence of 
comorbidity were predictive of poorer survival [Yousaf N et al, Clin Sarcoma 
Res. 2015].  
These studies suggest that some parameters may help clinical decisions, yet such 
clinical variables have not been validated in patients with STS.  
 
1.5.2 Molecular markers 
To date, molecular biomarkers for STS patient stratification that may add 
prognostic information or help predicting response to treatment are not yet well 
documented. 
The combination of high heterogeneity, both intratumoral and intertumoral, with 
their rarity has made diagnosis and prognosis of high-grade sarcomas difficult. 
A number of markers have been suggested, among which nuclear expression of 




of radiotherapy were shown to be associated with worse survival in patients with 
SS [Palmerini E et al, Orph J Rare Disease. 2014].  
Recent research has included the use of next generation sequencing or mass 
spectrometry imaging to find out possible biomarkers in STS. Microarray-based 
comparative genomic hybridization and mRNA expression profiling have 
identified some genomic alterations and candidate genes for discrimination of 
sarcoma subtypes, for disease progression, and as potential therapeutic targets 
[Fritz et al, Cancer Res. 2002; Adamowicz et al, Genes Chromosomes Cancer. 
2006; Francis et al, Biomed Chromatogr Genomics. 2007], though exploratory in 
nature so far.  
Among possible biomarkers, microRNAs and transcripts related to Epithelial to 
Mesenchymal Transition (EMT) and Mesenchymal to Epithelial Transition 
(MET) are promising, and therefore we decided to evaluate such biomarkers in 
our translational study.  
 
1.5.3 Markers related to Epithelial to Mesenchymal Transition (EMT) 
Phenotypic plasticity is the ability of an organism to change its phenotype in 
response to changes in the environment [Price TD et al, Proc Biol Sci. 2003].  
In cancer, phenotypic plasticity involves a process in which cells transiently 
acquire phenotypic traits of another lineage. The two most commonly studied 
types of plasticity are epithelial to mesenchymal transition (EMT) and its reverse 
process, mesenchymal to epithelial transition (MET). 
Epithelial cells have an apico-basal axis of polarity and form layers in close 
contact with each other, whereas mesenchymal cells are loosely organized in a 
three-dimensional extracellular matrix, in which they are more motile.  
EMT is a complex and reversible biological process involving a functional 
transition of epithelial cells into mobile mesenchymal cells [Kalluri R, Weinberg 
RA. J Clin. Invest. 2009; Thiery JP et al, Nat Rev Mol Cell Biol. 2006].  
Emerging evidence suggests that EMT contributes to metastatization and 
recurrence in most carcinomas, as well as in sarcoma  [Franco-Chuaire ML et al, 
Invest Clin. 2013; Liang YJ et al, Carcinogenesis. 2013].  
In carcinomas, EMT drives invasion and metastatic dissemination, while MET is 
suggested to play a role in metastatic colonization [Diepenbruck M, Christofori G. 








Figure 1: EMT/MET role in tumor invasion and progression.   
Induction of EMT in epithelial tumor cells has been shown to enhance migration, 
invasion and cancer ‘stemness’. Induction of MET facilitates metastatic 














Phenotypic plasticity in sarcomas is not well studied; however, there is evidence 
that a subset of sarcomas undergo a MET-like phenomenon. The exact 
mechanisms by which these transitions occur is still largely unknown, yet it is 
likely that some of the regulators that drive EMT and MET in carcinomas also 
play a role in sarcomas.  
The transcription factors (TF) families Snail (zinc finger proteins Snail and Slug), 
Zeb (zinc finger and homeodomain proteins ZEB-1 and ZEB-2) and Twist (basic 
helix–loop–helix proteins E12, E47, Twist1, Twist2 and Id) play a central role in 
EMT during organogenesis and tumorigenesis and are considered master EMT TF 
[Thiery JP et al, Cell. 2009; Polyak K et al, Nat Rev Cancer. 2009]. They are 
potent inducers of the epithelial cell dedifferentiation process by acting as 
transcriptional repressors of epithelial genes, including E-cadherin, and activators 
of mesenchymal genes, including N-cadherin [Lamouille S et al, Nat Rev Mol 
Cell Biol. 2014]. 
Key molecules related to a more polarized, “epithelial” status are E-cadherin and 
ZO-1.  
E-cadherin is a calcium-dependent cell-cell adhesion molecule with pivotal roles 
in epithelial cell behavior, tissue formation, and suppression of cancer [van Roy F, 
Berx G. Cell Mol Life Sci. 2008].  
ZO-1, protein of Zonula occludens-1, also known as Tight junction protein-1, is a 
protein located on the cytoplasmic membrane surface of intercellular tight 
junctions, with a putative role in signal transduction at cell–cell junctions 
[Stevenson BR et al, J Cell Biol. 1986]. 
The most commonly referred mesenchymal markers are vimentin and N-cadherin. 
Others include alpha-smooth muscle actin (alpha-SMA), desmin, alpha-actin, 
fibronectin, synaptophysin [Yang J et al,  Eur J Cancer. 2014] and periostin.  
Vimentin is a type-III intermediate filament normally expressed in mesenchymal 
cells, and its expression has been reported in epithelial cells involved in 
organogenesis, wound healing and tumour invasion [Lahat G et al, PLoS One. 
2010]. 
N-cadherin is a transmembrane adhesion glycoprotein whose forced expression 
leads to downregulation of E-cadherin expression and enhancement of  cancer cell 
motility and migration [Yang J et al, Mol Cell Proteomics. 2010]. N-cadherin has 




World J Urol; Aleskandarany MA et al, Breast Cancer Res Treat. 2015].  
Alpha-SMA is the actin isoform typical of vascular smooth muscle cells. Actins 
are highly conserved proteins that are involved in cell motility, structure and 
integrity. Alpha-SMA is particularly helpful in diagnosis of smooth muscle 
differentiation of soft tissue neoplastic masses [Skalli O et al,  J Cell Biol. 1986]. 
 
Periostin, also known as osteoblast-specific factor 2, is a multifunctional 
glycoprotein that belongs to the group of matricellular proteins. 
It was originally discovered in mesenchymal cells (osteoblasts, osteoblast-derived 
cells, periosteum).  
Periostin serves as a ligand for alpha-V/beta-3 and alpha-V/beta-5 integrins, and 
through the integrin-binding domains it interacts with several integrin receptors 
thus affecting the regulation of the intracellular signaling pathways associated 
with protein kinases PI3K/AKT and focal adhesion kinase (FAK), supporting 
adhesion and migration of epithelial cells [Gillan L et al, Cancer Research. 2002]. 
Through its influence on extracellular matrix restructuring and tissue remodeling, 
it plays major roles in tissue healing, development, and disease [Conway SJ et al, 
Cell Mol Life Sci. 2014].  
Periostin has been found to have a key role in tumorigenesis and  EMT in several 
types of tumors [Chen M et al, J Neurol Sci. 2016]. In many cancers, Periostin 
binds to integrins on cancer cells, activating signaling pathways that ultimately 
lead to increased cell survival, invasion, angiogenesis and metastasis.  
Periostin has been recently associated with poor outcomes in osteosarcoma, but no 
data are available so far for STS [Hu F et al, Int J Exp Pathol. 2016].  
Because of the connection of EMT with cancer, the attention of the scientific 
community has been directed towards the search for and identification of effective 
therapeutic targets. Such targets include signal transduction in tumor cells and the 
use of microRNAs, which would play a role in EMT-associated phenotypic 
changes and tumoral progression.   
 
1.5.4 microRNAs (miRNAs) 
MicroRNAs (miRNAs), which are small, noncoding RNA molecules of 20–24 
nucleotides, have a major role in RNA silencing and post-transcriptional 




transcriptional and/or transcriptional level through targeting the 3’-untranslated 
regions of mRNAs. 
Early studies have highlighted the role of miRNAs in physiological processes, and 
how their deregulation can lead to cancer. The causes of abnormal miRNA 
expression in cancer cells are only partially understood, and suggested 
mechanisms are abnormalities in miRNA-processing genes and proteins, and 
epigenetic regulation of miRNA expression [Calin GA, Croce CM. Nat Rev 
Cancer. 2006]. It has been reported that almost every type of cancer, including 
sarcoma, displays a specific profile of aberrantly expressed miRNAs that might be 
used as potential biomarkers or as therapeutic targets [Winter J et al, Nat Cell 
Biol. 2009; Jiang B et al, J Exp Clin Cancer Res. 2016; Chen W et al, J Exp Clin 
Cancer Res. 2016;  Lauvrak SU et al, Br J Cancer. 2013; Li J et al, Cell Prolif. 
2014]. 
miRNAs are therefore considered attractive candidates that may improve 
diagnostic, prognostic, and predictive characterization of this group of 
malignancies [Ryan BM et al, Nat Rev Cancer. 2010]. 
Recent publications suggest that different histological subtypes of sarcomas may 
have distinct miRNA expression patterns [Subramanian S et al, Oncogene 2008; 
Ugras S et al, Cancer Res 2011]. 
A recent study has shown a miRNA set in high grade sarcomas that could have an 
important role in the process of sarcomagenesis [Renner M et al, Gene, 
Chromosome and Cancer. 2012], Figure 2. 
In this work, by means of hierarchical clustering of miRNA expression data from 
76 sarcoma samples in an unsupervised manner, four main sarcoma subgroups 
were identified.  One subgroup consisted mainly of SS, a second subgroup was 
formed exclusively by LMS, a third subgroup consisted mainly of mixoid 
liposarcoma (MLS) and the remaining sarcoma samples, that could not be further 
subdivided, were composed of dedifferentiated LPS, pleomorphic LPS, UPS, 
MFS, malignant peripheral nerve sheath tumor (MPNST), SS and MLS, and three 
samples of LMS. Within this subgroup five out of eight MPNST samples grouped 
together according to their diagnosis [Renner M et al, Gene, Chromosome and 
Cancer. 2012].  
In this series, some miRNAs, and specifically miR-133a-3p, miR-133b, and miR-




called myo-miRNAs. They have been shown to play a major role in skeletal 
muscle proliferation and differentiation [Chen JF et al, Nat Genet. 2006]. Thus, 
miR-133a/b and miR-1 may be possibly involved in the malignant transformation 
of smooth muscle cells to LMS.  
miR-1 has been suggested to function as a tumor suppressor in a variety of human 
cancers, since it inhibits proliferation, migration, and invasion, through the 
repression of  several oncogenes (i.e. c-MET, Pim-1) and other molecules such as 
Vascular Endothelial Growth Factor-A (VEGFA) [Nasser MW et al,  J Biol 
Chem. 2008; Niu J et al, Dis Markers. 2016].  
Beyond a putative, direct role of miRNAs in the pathogenesis of STS, there is 
accumulating evidence on the inter-play between miRNAs and EMT markers in 
cancer cells [Liang YJ et al, Carcinogenesis. 2013; Fan Z et al, Oncotarget. 2015].   
Indeed, several miRNAs promote or suppress EMT through direct or indirect 
modulation of the expression of EMT-related traits or transcription factors [Ma L 
et al, Nat Cell Biol. 2010; Williams LV et al, PLoS ONE. 2013; Bracken CP et al, 
Cancer Res. 2008]. Their role may be sometimes controversial due to the 
pleiotropic properties some of them display.  
Among these, miR-100-5p is believed to be one of the drivers of EMT, yet at the 
same time it can suppress tumorigenesis, migration and invasion [Chen D et al, 
PLoS Genet. 2014].  
Also, there are data on the role of combined expression of the mir-200 family and 
ZEB-1 with upregulation of an epithelial gene activator, GRHL2, in driving 
sarcoma cells to a more epithelial-like state, and such a regulatory network may 
have a prognostic relevance [Somarelli JA et al, Mol Cell Biol. 2016]. 
Both miR-1 and miR-200 target Slug, and this way inhibits EMT. Actually, both 
miR-1 and miR-200 have a role in inhibition of EMT via Slug-dependent and in 
inhibition of tumorigenesis via Slug-independent mechanisms [Liu YN et al, 
Oncogene 2013].  Other miRNAs known to be EMT modulators are miR-30 
family. In particular, miR-30b has been shown to inhibit EMT by targeting Snail, 
and by blocking TGF-β1-induced EMT [Zhang J et al, Biochem Biophys Res 
Commun. 2012; Zhong Z et al, Mol Med Rep. 2014]. 
In STS, data on the role of miRNAs and correlation with EMT are scarce, and 
evaluation of such markers could be useful in order to highlight possible 






Figure 2: Unsupervised hierarchical clustering of miRNA expression data of 76 
untreated, primary high-grade sarcoma samples [from Renner M et al. Gene, 




AIM OF THE STUDY  
 
The aims of this study were: 
1. to describe efficacy and toxicity of chemotherapy  for advanced STS in a cohort 
of unselected patients treated at Istituto Oncologico Veneto IOV – IRCCS, and to 
evaluate possible clinical predictors of outcome;  
2. to study the expression of biomarkers in different sarcoma histological types in 
order to evaluate possible histological-specific profiles 





























PATIENTS AND METHODS  
 
Clinical evaluation of pts referred to Medical Oncology Unit 1 – IOV  
This is a mono-institutional exploratory prospective pilot study conducted at the 
Istituto Oncologico Veneto IOV - IRCCS  di Padova.  
Patients referred to Medical Oncology 1 Unit, at Istituto Oncologico Veneto, from 
January 2010 to December 2015 were identified via a prospectively maintained 
sarcoma database.  
Only patients with locally advanced STS, deemed not amenable to surgical 
resection, or those with metastatic disease were included. Patients with a 
diagnosis of GIST and primary bone sarcomas were excluded. 
Data regarding each patient were retrospectively collected from electronic medical 
records. Date of diagnosis, age at diagnosis, site of metastasis, chemotherapy 
agents used, performance status, serum albumin, LDH, lymphocyte and neutrophil 
count, date of death or last follow-up were collected.  Response was evaluated by 
means of the RECIST criteria, version 1.1 for all the patients in which this was 
possible.  
The clinical outcome of each patient was recorded as alive or dead as of 
September 30th  2016. Laboratory ranges for blood parameters were as follows; 
serum albumin (normal range 35 – 50 g/L), LDH (normal range 100–280 U/L), 
lymphocytes (normal range 1.3 – 3.5 ×109/L), neutrophils (normal range 1.80 – 
7.80 ×109/L) and haemoglobin (normal range, male 13 – 16.5 g/dL, female 11.5 – 
15 g/dl). 
 
Translational study  
Tumor tissues from patients affected by STS referred to the Istituto Oncologico 
Veneto, Padova, were either retrieved from the Tissue Biobank of the Department 
of Surgical, Oncological and Gastroenterological Sciences, University of Padova,  
or freshly received as tru-cut biopsy or surgical specimen.  
Eligible histological types were leiomyosarcoma (LMS), undifferentiated 
pleomorphic sarcoma (UPS), and fibromyxosarcoma (MFS). Low-grade 
fibromyxoid sarcomas (FMS) were also analyzed. 
All the specimens were reviewed by an expert pathologist for confirmation of 




to September 2016.  
Markers linked to EMT/MET were analysed by qRT-PCR as previously reported 
[Lignitto et al, Cancer Med. 2014], using primers specific for epithelial markers 
(E-cadherin and ZO-1), and mesenchymal markers (Snail, Slug, Vimentin, Zeb−1, 
Zeb−2, and N-cadherin). Expression of alpha-SMA, a smooth muscle-derivation 
marker widely used for immunohistochemical diagnosis of LMS, was also 
evaluated, along with Periostin. 
The expression of specific miRNAs linked to EMT (miR-100-5p-5p), to MET 
(miR200b-3p, miR30b-5p and miR30c-5p), and myo-miRNAs (miR-1, miR 133a-
3p and 133b) was assessed by MicroRNA locked nucleic acids (LNATM) PCR 
primer sets (Exiqon A/S, Denmark). These PCR amplification primers offer a 
high sensitivity, low background and accurate quantification of low microRNA 
levels. The high specificity allows the discrimination between closely related 
microRNA sequences. 
10 ng RNA of each sample was reverse transcribed to cDNA using miRCURY 
LNATM Universal reverse trancription (RT) microRNA PCR cDNA synthesis 
Kit (Exiqon A/S Denmark) according to the manufacturer's protocol. The assays 
were performed in duplicate on the ABI 7900HT RealTime PCR system (Applied 
Biosystem, Foster City, CA, USA).  
To evaluate differences in efficiencies in RNA isolation, cDNA synthesis and 
PCR amplification, known spike-ins (RNA spike-ins, Exiqon A/S Denmark ) were 
added into the sample prior to RNA isolation (UniSp2, UniSp4, UniSp5) and prior 
to cDNA synthesis (UniSp6) following the manufacturer's protocol. The relative 
quantification (RQ) of miRNAs were standardized to U6 as endogenous control 
and calculated using 2-∆∆Ct method [Livak KJ and Schmittgen TD, Methods 
2001]. 
These analyses were conducted in the laboratory of Dr. ML Calabrò.  
The study was approved by the Institutional Ethics Committee in November 2014, 
and conducted in accordance with the Helsinki Declaration and Good Clinical 










Clinical evaluation of pts referred to Medical Oncology Unit 1 -   IOV  
Overall survival was measured from the start of chemotherapy to the time of death 
and censored at last follow-up. Survival was estimated with the Kaplan–Meier 
product-limit method, comparisons between groups were performed using the log-
rank test. Univariate and multivariate analysis and hazard ratio (HR) were 
calculated using Cox regression. 
 
Translational study 
The distributions of biomarkers among categories of clinical variables, such as 
grade and histotype, were compared by the Kruskal-Wallis test and relationships 
among all biological variables were explored by means of the Spearman rank 
correlation coefficient.  
Overall survival was defined as the time from diagnosis until death. Survival 
probabilities were calculated with the Kaplan-Meier method and the log-rank test 
was used to test for differences between clinical and biological categories. Each 
biomarker was dichotomized and classified according to the median value.  
Hazard ratios (HR) and their 95% confidence interval (95%CI) based on the Cox 
proportional hazards model were estimated to test the association between clinical 
and biological characteristics and the risk of death.  
The proportionality assumption was tested by including time-dependent covariates 
in each model. 
Multiple Cox models were used to determine the adjusted association of clinical 
and biological factors on the probability of failure.  
All tests were two-sided, and a P < 0.05 was considered statistically significant. 













4.1 Clinical evaluation of pts referred to Medical Oncology Unit 1 – Istituto 
Oncologico Veneto  IRCCS. 
 
4.1.1 Patients’ characteristics 
We identified a total of 405 patients with STS referred to Medical Oncology 1 at 
Istituto Oncologico Veneto from January 2010 to December 2015. 
Two-hundred and eight patients (51.4%) had advanced or metastatic disease. 
Forty-one patients were seen for consultation only and were treated elsewhere, 
therefore were excluded from the analysis.  
One hundred-sixty seven patients were taken in charge at Istituto Oncologico 
Veneto. Median age was 61 years (range 16-89), 87 patients (52.1%) were female, 
and 54 (32.3%) were aged ≥ 70 years.  
Out of these, 37 patients (19.8%) did not receive chemotherapy:  five patients 
underwent surgical metastasectomy, 9 patients received palliative radiotherapy 
only and 21 did not receive any active oncological treatment because of severe 
comorbidity. 
Patients’ characteristics are described in Table 2.  
 
4.1.2 Chemotherapy response and toxicity  
One hundred-thirty patients were treated for advanced disease at Istituto 
Oncologico Veneto.  
Patients receiving only first-line chemotherapy were 57 (34.1%), patients 
receiving two lines of chemotherapy were 30 (18%), and 43 patients (25.7%) 
received more than two lines of chemotherapy.  
First-line chemotherapy regimens were anthracycline-based, either doxorubicin 
single-agent or a combination of epirubicin and ifosfamide) in 81 patients 
(62.3%). In 13 patients (10%) first-line regimen was high-dose infusional 
ifosfamide, 12 patients (9.2%) received trabectedin and 24 patients (18.5%) 
received other regimens (gemcitabine-based regimens, tyrosine-kinase inhibitors, 





A complete response to first-line therapy was observed in three patients (2.3%), 
partial response was reported in 33 patients (25.4%), with disease stabilisation 
(clinical benefit) in further 38 patients (29.2%), whereas progressive disease as 
best response was reported in 45 patients (34.7%).  
Grade ≥3 toxicities occurred in 59 patients (45.4%), and 23 patients (17.7%) 
required hospitalization for toxicity management. Hematological grade 3 or 4 
toxicity developed in 40 patients (30.8%), with febrile neutropenia being the most 
prevalent (14 patients, 10.8%). Eighteen patients (13.8%) presented grade ≥3 
extra-hematological toxicity, mainly mucositis (2 patients), nausea and vomiting 
(2 patients), cardiac toxicity (1 patient).  
 
4.1.3 Survival 
For patients with advanced or metastatic disease, with a median follow-up time of 
12.8 months (0.07-83.43), median OS was 17.7 months (95%CI 13.59-21.75), and 
median PFS was 10 months (95%CI 7.9-12.0); Figures 3 and 4. 
Median OS of patients treated with chemotherapy was 19.9 months (95%CI 16.4–
23.5), while that of untreated patients was 3.3 months (95%CI 1.3-5.2), p<0.001; 
Figure 5. 
At univariate analysis, ECOG PS, anemia and lymphopenia 
(neutrophils/lymphocytes ratio ≥3), were associated with prognosis; Table 3.  
Patients with PS 0 had better median OS compared to those with PS 1 and PS 2-3, 
respectively 23.5 months (CI 95% 18.5–28.5), 15.8 months (95%CI 18.5–28.5), 
 6.6 months (95%CI 1.0-12.3), p< 0.001; Figure 6.  
Baseline low lymphocyte count, with neutrophil/lymphocyte ratio ≥3 was 
associated with worse survival, with median OS 12.5 months (95%CI 5.4-19.5) 
compared to patients with neutrophil/lymphocyte ratio <3, who had median OS 
22.8 months (95%CI 15.2-30.4), p=0.005; Figure 7.  
Baseline anemia was also associated with worse survival, with median OS for 
anemic patients (Hb<12 g/dL) being 9 months (95%CI 3.2-14.8) and median OS 
for non-anemic patients being 20.9 months (95%CI 16.6-25.4); Figure 8.  
No difference in OS was seen according to age, gender, chemotherapy regimen, 
BMI, albumin levels, or LDH levels.  
We found baseline anemia and lymphopenia were associated, OR 5.56 (95%CI 




analysis. In multivariate analysis, ECOG PS and lymphopenia were confirmed to 
be associated with worse survival; Table 4.  
No differences according to all explored variables were observed for PFS.  
 
 
Table 2: Characteristics of patients with advanced STS treated at IOV  (N=167) 
  N (%) 
















































Site of metastases  Lung and extra-pulmonary 
Locally advanced/inoperable 






Previous treatment for 
localized disease   
None 
Previous (neo)adjuvant therapy 






























Table 3: Univariate analysis for OS  
Variable B SE Wald d
f 
p value HR HR 95% CI 
Age (continuous)  0,005 0,007 0,7 1 0,403 1,005 0,993 - 1,018 
Histological type   
LMS  0,570 0,752 0,575 1 0,448 1,768 0,405 - 7,715 
Liposarcoma  0,580 0,738 0,618 1 0,432 1,786 0,420 - 7,588 
MFS  1,527 1,009 2,288 1 0,130 4,603 0,637 - 33,285 
MPNSC  0,476 1,002 0,226 1 0,635 1,610 0,226 - 11,478 
SS 0,490 0,818 0,359 1 0,549 1,633 0,328 - 8,118 
UPS  0,491 0,785 0,392 1 0,531 1,634 0,351 - 7,614 
Other  0,565 0,733 0,594 1 0,441 1,760 0,418 - 7,405 
PS   
1 vs. 0 0,551 0,232 5,643 1 0,018* 1,735 1,101 - 2,733 
2-3 vs. 0 1,233 0,352 12,28
2 
1 < 0.001* 3,43 1,722 - 6,833 
Site of metastases   
Locally Advanced  -0,645 0,372 3,014 1 0,083 0,525 0,253 - 1,087 
Lung and Extra-pulmonary 0,346 0,286 1,460 1 0,227 1,413 0,806 - 2,477 
Extra-pulmonary  0,237 0,330 0,518 1 0,472 1,268 0,664 - 2,420 
First line CT regimen   
HD-IFO vs. Anthra-Based 0,041 0,379 0,012 1 0,914 1,042 0,495 - 2,190 
Trabectedin vs. Anthra-Based -0,129 0,359 0,130 1 0,719 0,879 0,435 - 1,775 
Other vs. Anthra-Based -0,422 0,317 1,771 1 0,183 0,656 0,352 - 1,221 
N/L  
Yes vs. No 0,680 0,247 7,619 1 0,006* 1,975 1,218 - 3,201 
Albumin levels  (N=88)  
Low vs. Normal 0,059 0,324 0,033 1 0,855 1,061 0,563 - 2 
LDH (N=85)  
High vs. Normal 0,116 0,293 0,158 1 0,691 1,124 0,632 - 1,996 
N. lines of treatment   
Two Lines vs. more than two 0,073 0,278 0,068 1 0,794 1,075 0,623 - 1,855 
One Lines vs. more than two 0,129 0,243 0,282 1 0,596 1,138 0,707 - 1,831 
Anemia   
Yes vs. No  0.446 0.236 3.565 1 0.059* 1.563 0.983-2.484 
*significant factors in univariate analysis 
 
Table 4: Multivariate analysis for OS  
Variable B SE Wald df p value HR HR 95% CI  
PS   
1 vs. 0 0,45 0,282 2,538 1 0,111 1,568 0,902 2,728 
2-3 vs. 0 0,8 0,411 3,791 1 0,052* 2,225 0,995 4,979 
N/L  
Yes vs. No 0,671 0,307 4,792 1 0,029* 1,956 1,073 3,568 
Anemia          
Yes vs. No 0,944 0,558 2,868 1 0,09 2,571 0,862 7,668 
Anemia*N/L -1,076 0,649 2,753 1 0,097 0,341 0,096 1,215 





Figure 3: OS for advanced STS patients (N=167; 121 events). 
 
 
                       
 








Figure 5: OS according to chemotherapy administration. 
OS for patients treated with first-line chemotherapy  (thick line, 130 patients, 90 




Figure 6: OS according to Performance Status  (0 vs 1 vs 2-3). 
OS for patients with PS 0 (thick line, 61 patients, 41 events),  PS 1 (thin line, 45 






         
Figure 7: OS according to lymphopenia.  
OS for patients with neutrophil/lymphocyte ratio <3 (thick line, 49 patients, 28 
events) and for patients with neutrophil/lymphocyte ratio ≥3 (dotted line, 52 





Figure 8: OS according to anemia.   
OS for patients with Hb>12 g/dL (thick line, 80 patients, 53 events) and for 







4.2 Translational study  
 
4.2.1 Samples   
Overall, sixty-seven STS samples were initially included in the translational stydy 
specifically 30 LMS, of which 10 low/intermediate grade (LG) and 20 high grade 
(HG) LMS; 22 myxoid sarcomas (of which 17 MFS/ and 5 low-grade FMS); and 
15 UPS. The quantitative evaluation of biomarkers was limited by the low amount 
of RNA extracted from 12 samples. Therefore the complete molecular 
characterization was carried out in 54 samples, whose characteristics are described 
in Table 5. 
 
4.2.2 Markers distribution  
EMT-related transcripts and microRNAs distribution in our samples are described 
in Table 6. 
Markers’ distribution according to tumor grade is shown in Table 7. 
Neither EMT-related transcripts nor microRNAs were found to be correlated with 
tumor grade.  
 
4.2.3 Evaluation of EMT transcripts   
The samples were analysed for the expression of E-cadherin and ZO-1, as 
epithelial markers, and of Slug, Vimentin, Snail, ZEB-1, ZEB-2, N-cadherin, and 
Periostin, as markers related to a mesenchymal status. 
EMT-related transcripts expression for each considered histological type is shown 
in Figure 10. 
E-cadherin expression was not found in all analysed STS. 
In LMS, two distinct pattern of expression of EMT-related markers can be 
observed, with the presence of such patterns in both LG and HG LMS. 
In MFS the expression of EMT-related transcripts is constantly low, and grading-
independent. 







Table 5: Sample characteristics (N=55) 
Variable     
Grade G1 3 5.45% 
 G2 14 25.45% 
 G3 38 69.09% 
Histotype  LMS 28 50.91% 
 MFS 13 23.64% 
 UPS 14 25.45% 
Metastases at diagnosis  No 46 85.19% 
 Yes 8 14.81% 
 Missing 1  
Tumor size  ≥5 cm 42 80.77% 
 <5 cm 10 19.23% 
 Missing 3  
Living status  Alive 26 47.27% 
 Dead 29 52.73% 
Relapse No 19 38.00% 
 Yes 31 62.00% 
 Missing 5  
	  	  	  	  
Table 6: Markers distribution in all histological types:  (a) EMT-related 
transcripts and (b) miRNAs  
	  








Quartile Min Max 
N_CAD 46 4.5 7.6 1.3 0.2 4 0 32.5 
PERIOSTIN 43 4.6 7.4 2.4 0.2 5.9 0 36.8 
SLUG 49 1.7 2.1 1.1 0.3 1.9 0 9.7 
Alpha-SMA 49 61.5 192.9 1.2 0.3 13.4 0 973.1 
SNAIL 46 2.1 3.7 1 0.3 2.5 0 22.5 
VIMENTIN 49 2 3.2 1.3 0.6 2.4 0.1 20.9 
ZEB-1 45 157.3 404.1 0.4 0.2 95.4 0 1674.2 
ZEB-2 45 5.5 19.4 0.9 0.5 3.1 0.1 129.1 









Quartile  Min Max 
miR-1 49 60.7 221.1 1.2 0.2 16.5 0 1500.2 
miR-100-5p-5p 49 4.8 9.1 1.8 0.6 5.7 0 59.3 
miR-133a-3p 49 49.6 165.6 1.9 0.2 24 0 1096.9 
miR-133b 49 54.9 187.7 2.2 0.2 25.8 0 1247.3 
miR-200b-3p 44 3 7.3 0.8 0.4 1.9 0 39.6 
miR-30b-5p 49 1.7 1.9 1 0.6 1.9 0.1 9.1 







Table 7: Markers distribution according to grade: (a) EMT-related 
transcripts and (b) miRNAs  
 
a) EMT-related transcripts  
 
Variable N Grade 
Mean 




Quartile Min Max 
p-value 
(KW) 
N_CAD 13 G1+G2 3.6 6.5 1.2 0.3 2.2 0.1 21 0.6256 
 33 G3 4.8 8.1 1.4 0.2 5.5 0 32.5  
PERIOSTIN 12 G1+G2 1.9 2.2 1.1 0.3 2.7 0 7.3 0.2079 
 31 G3 5.7 8.4 2.7 0.2 7.3 0.1 36.8  
SLUG 14 G1+G2 1.6 2.2 1.2 0.3 1.9 0.1 8.8 0.8505 
 35 G3 1.8 2.1 1.1 0.3 2 0 9.7  
Alpha-SMA 14 G1+G2 108.9 248.9 2.7 0.3 56.8 0 806.5 0.3518 
 35 G3 42.5 166 0.9 0.2 12.5 0 973.1  
SNAIL 13 G1+G2 2.9 6.1 1 0.3 2.6 0.1 22.5 0.5746 
 33 G3 1.8 2.2 1.2 0.4 2.2 0 8.9  
VIMENTIN 14 G1+G2 3.3 5.5 1.5 0.6 2.6 0.1 20.9 0.6027 
 35 G3 1.6 1.3 1.2 0.5 2.2 0.2 5.5  
ZEB-1 13 G1+G2 188.1 461 0.4 0.2 1.8 0 1578.5 0.5973 
 32 G3 144.8 386 0.5 0.2 129.6 0.1 1674.2  
ZEB-2 13 G1+G2 3.3 6.5 0.6 0.3 1.8 0.1 22.5 0.1759 
 32 G3 6.4 22.6 1 0.7 3.6 0.1 129.1  
ZO_1 14 G1+G2 6.6 12.3 1.1 0.3 6.8 0.1 44.1 0.7393 





Variable N Grade 
Mean 




Quartile Min Max 
p-value 
(KW) 
miR-1 17 G1+G2 24.4 47.8 3 0.2 7.8 0.1 164.1 0.5706 
 32 G3 80 271 0.6 0.2 25.4 0 1500.2  
miR-100-5p 17 G1+G2 3.8 5 1.7 0.9 5.9 0 18.2 0.6290 
 32 G3 5.4 10.7 2.2 0.6 5.4 0 59.3  
miR-133a-3p 17 G1+G2 22.5 43.3 4.9 0.4 20.6 0.1 168.5 0.4371 
 32 G3 64 202.2 0.8 0.1 35.3 0 1096.9  
miR-133b 17 G1+G2 25.7 50.9 6.6 0.2 25.8 0.1 203.5 0.4751 
 32 G3 70.4 229.1 1.2 0.2 32 0 1247.3  
miR200b-3p 15 G1+G2 5.9 11.9 0.8 0.5 2.5 0.3 39.6 0.2298 
 29 G3 1.4 1.7 0.9 0.3 1.9 0 6.8  
miR30b-5p 17 G1+G2 1.8 2.5 1 0.5 1.6 0.1 9.1 0.7687 
 32 G3 1.6 1.5 1 0.7 1.9 0.1 6.7  
miR30c-5p 17 G1+G2 2.1 3.8 1 0.5 1.4 0.2 15.5 0.6898 












Figure 10: Global expression profile of EMT-related transcripts according to 
histological subtype.  
EMT-related transcripts expression (nRQ) in LMS, MFS and UPS. Values have been 






More in detail, as for the expression of the transcripts of ZO-1, Slug, Vimentin 
and Snail, no significant difference was found in the three histological types. 
Also, no difference was observed in the expression of such markers between HG 
and LG LMS; Figure 11.  
Alpha-SMA was significantly expressed in LMS compared to UPS and MFS/FMS 
(p<0.001), and not significantly different in UPS compared to MFS/FMS, Figure 
12.  
 
ZEB-1 and ZEB-2 expression was significantly higher in LMS compared to 
MFS/FMS (p<0.001) and UPS (p=0.001 for ZEB-1, p=0.003 for ZEB-2), whereas 
no differential expression was measured between UPS and MFS/FMS. 
Interestingly, ZEB-1 and ZEB-2 were differentially expressed in HG and LG 
LMS (p=0.038 for ZEB-1, p=0.048 for ZEB-2);  Figure 13.  
Also N-cadherin expression was significantly higher in LMS compared to 
MFS/FMS (p=0.006) and UPS (p=0.028), whereas no differential  expression was 
measured according to the grading; Figure 14.   
 
As for periostin, this was found to be higher in LMS compared to MFS/FMS 
(p=0.002), and in UPS compared to MFS/FMS (p=0.005), no difference was 


















Figure 11: Expression of ZO-1, Slug, Vimentin and Snail.     
Box plots describing expression (nRQ) of ZO-1, Slug, Vimentin and Snail 








                  
Figure 12: Expression of alpha-SMA.    
Box plots describing expression (nRQ) of alpha-SMA according to histological 






Figure 13: Expression of ZEB-1 and ZEB-2.    
Box plots describing expression (nRQ) of ZEB-1 and ZEB-2  according to 











Figure 14: Expression of N-cadherin. 
Box plots describing expression (nRQ) of  N-cadherin  according to histological 








                       
Figure 15: Expression of Periostin. 
Box plots describing expression (nRQ) of Periostin  according to histological 










4.2.4 Evaluation of microRNAs   
The expression of miRNAs in the three histological types is shown in Figure 16. 
In our samples miR-1, miR-133a-3p and miR-133b (“myo-miRNAs”) expression 
was found to be significantly higher in LMS compared to MFS and UPS 
(p=0.002) though no difference was observed between HG and LG LMS; Figure 
17. 
All other analysed miRNAs did not show a different expression in the three 
histological subtypes, nor it was different according to grade, with the exception 
of miR-100-5p, which was found to be significantly over-expressed in LMS 
compared to MFS/FMS (p=0.02); Figures 18-20.  
 
 
4.2.5 Correlation of EMT-related markers and miRNAs    
In our samples, we observed an inverse correlation between Slug and myo-
miRNAs expression; Figure 21.  
Also, a direct correlation between ZEB family members, and an inverse 















Figure 16: Global profile of analysed miRNAs. 
Global expression profiles of miRNAs in all analysed miRNAS in LMS, MFS and UPS. 




Figure 17: miR-1, miR-133a-3p and miR-133b (“myo-miRNAs”) expression 
according to histological type. 
Expression profiles of myo-miRNAs according to histological subtype, and 






Figure 18: : miR-100-5p  expression according to histological type. 
Expression profiles of miR-100-5p according to histological subtype, and 







Figure 19: miR-30b and miR-30c  expression according to histological type. 
Expression profiles of miR-30b and miR-30c according to histological subtype, 





Figure 20: miR-200  expression according to histological type.  
Expression profiles of miR-200 according to histological subtype, and according 












Figure 21: Expression of Slug and myo-miRNAs.  







Figure 22: ZEB-family and miR-200b correlation.   
The expression shows a direct correlation between  ZEB-1 and ZEB-2; there is an 
inverse correlation, with a trend to statistical significance, between the expression 










4.2.6 Correlation of biomarkers with survival  
 
In univariate analysis for OS there was a significant correlation between grade, 
metastatic stage at diagnosis, histological subtypes and survival; Table 8 and 
Figure 23.  
 
Taking into consideration biological variables, there was a trend to significant 
correlation between ZEB-1 and ZEB-2 and OS. Taking as a cut-off threshold the 
median value, high ZEB-1 (≥0.4) was correlated with worse OS (2.3 months, 
95%CI 0.9-3.4) vs low ZEB-1 (8.6 months, 1.5 – n.r.), p=0.058. 
Similarly, high ZEB-2 (≥0.9) was correlated with worse OS (2.2 months, 95%CI 
0.9-32.7) vs low ZEB-2 (8.6 months, 1.5 – n.r.), p=0.052. 
The other marker that was significantly associated with survival in univariate 
analysis was Periostin.Taking as a cut-off threshold the median value, high 
Periostin (≥2.4) was correlated with worse OS (2.2 months, 95%CI 1.2-2.5) vs 
low Periostin (8.6 months, 1.3 – n.r.) , p=0.028; Figure 24.  
 
In multivariate analysis, grade, Periostin and ZEB-1 levels confirmed to be 
associated with overall survival, Table 9.  
 
All the other analysed EMT-related markers, as well as analysed miRNAs, were 

















Table 8:Univariate analysis for OS – clinical variables.  
 
Variable Events/n Median OS 
(95%CI) 
p-value log-rank HR (95% CI) (HR)  
p-value 
Grade (n=54)   0.0050   
G1-G2 4/16 - (2.70;-)  0.24 (0.08;0.70) 0.0091 
G3 25/38 2.16 (1.32;6.73)  1  
Metastases at diagnosis 
(n=53) 
  0.0261   
No 23/45 3.42 (2.03;-)  0.36 (0.14;0.92) 0.0320 
Yes 6/8 1.52 (0.11;7.67)  1  
Tumor size  (n=51)   0.1476   
≥5 cm 26/42 2.33 (1.47 ;8.01)  2.36 (0.71 ;7.81) 0.1599 
<5 cm 3/9 - (0.74 ;-)  1  
Histotype (n=54)   0.0944   
LMS 17/28 2.51 (2.02;7.67)  0.89 (0.39;2.01) 0.7806 
MFS 3/12 - (1.32 ;-)  0.27 (0.07 ;1.00) 0.0498 










Grade   
G1-G2 1  
G3 4.64 (1.48;14.52) 0.0083 
Histotype   
LMS 1  
MFS 0.27 (0.08;0.96) 0.0437 
UPS 0.37 (0.29;1.56) 0.3484 
Periostin   
<2.4 (median) 1  
>=2.4 2.22 (0.95;5.20) 0.0660 
   
ZEB-1   
<0.4 (median) 1  
>=0.4 2.33 (1.01;5.38) 0.0473 
ZEB-2   
<0.9 (median) 1  






























































































































































Clinical evaluation of pts referred to Medical Oncology Unit 1 – Istituto 
Oncologico Veneto IRCCS. 
In the retrospective analysis of real world data from 167 patients treated for 
advanced STS in our Institution in the past 5 years we have found that about one 
third of patients were aged 70 years and older, with median age of all patients 
being 61 years. This finding is in line with epidemiologic data, and raises some 
concerns on best treatment for these patients, given the under-representation of 
older patients in clinical trials 
Of all the patients with STS referred to our Medical Oncology Unit, about 35% 
were metastatic at diagnosis, and about 65% relapsed after primary tumor 
treatment, thus confirming the aggressive nature of STS. 
Our data confirm the role of anthracyclines in first-line treatment of STS, that 
allowed to obtain a clinical benefit (complete response + partial response + stable 
disease) in 57% of patients.  Yet, this efficacy results must be weighted against 
the burden of toxicity. In our study indeed about a half of patients had severe 
(grade 3 or 4) toxicity, and almost 20% of patients required hospitalization for 
toxicity-related reasons.  
These data suggest a high unmet need for more effective and less toxic treatment 
options for patients with advanced or metastatic STS. 
Globally, overall survival for the whole cohort of patients was in line with 
literature data and other published series, with a global median OS of 17.7 months  
Actually, in our series patients undergoing palliative chemotherapy showed higher 
OS rates when compared to published data, with median OS for treated patients 
being 19.9 months.  
Randomized trials of first-line chemotherapy have provided median OS for treated 
patients of about 14 months [Judson I et al, Lancet Oncol. 2014; Chawla SP et al, 
JAMA Oncol. 2015]. A series  from the Royal Marsden Hospital showed a 
median OS of about 12 month [Karavasilis V e al, Cancer. 2008]. In another 
recently published Australian series on 253 patients with advanced STS median 
OS for patients treated with chemotherapy, which were about one third of the 
whole sample, was 18 months [Bae S et al, Clin Sarcoma Res. 2016]. 
The retrospective study describing international treatment patterns Sarcoma 




has detected overall median overall survival rates from diagnosis of metastatic 
disease of 33.3 months [Leahy M et al, Ann Oncol. 2012], yet this study per 
inclusion criteria selected only patients not progressing on first line 
chemotherapy. 
Only roughly one fourth of patients received more than two lines of chemotherapy 
for advanced disease, and this could at least in part explain the difference in 
survival observed with other recent reports for patients who are able to undergo 
multiple lines of chemotherapy [Wagner MJ et al, BMC Cancer. 2015].  
As for chemotherapy response and toxicity, we were not able to assess the impact 
of specific chemotherapy agents on toxicity, response or survival due to the 
heterogeneity of regimes used.   
Yet, we could confirm the role of suggested prognostic clinical factor in our series 
of patients. In particular, better outcomes were associated with good general 
conditions, as represented by ECOG PS, whereas anemia and lymphopenia were 
predictors of worse survival. An interaction between anemia and lymphopenia 
was found, and this could explain results of the multivariate analysis, in which 
only PS and lymphopenia were predictors of survival.  
The lesser role of LDH or albumin levels on outcomes, which have been 
associated with prognosis in some other studies [Yousaf N et al, Clin Sarcoma 
Res. 2015], may be related to the high number of missing data for these variables.  
 
Translational study  
Soft tissue sarcomas constitute a group of highly aggressive, histologicallyand 
genetically heterogeneous malignant tumors of mesenchymal origin. 
To date, only for some histological types a specific underlying molecular event 
driving oncogenesis has been recognized thanks to gene expression profiling and 
other modern techniques. 
Despite progress made in the recent years, the vast majority of STS present a 
pleomorphic morphology, complex karyotypes and expression profiles [Nielsen 
TO, et al J Clin Oncol. 2010].  
Only few diagnostic and prognostic markers exist, and the cellular origin of 
several sarcoma subtypes is unknown, and this study was aimed at evaluating 




In particular, we focused on some biomarkers of EMT and MET, as well as on 
selected miRNAs, in both HG and LG pleomorphic STS samples.                                                                                                                                                                                   
 
Most published studies on EMT markers focus on metastatic carcinomas, and 
studies on sarcomas, namely bone sarcomas and STS, are few.  
In our study, EMT markers and explored miRNAs did not correlate with grade of 
STS. This could probably reflect the fact that STS are mesenchymal neoplasms 
and as such EMT-markers and EMT-related miRNAs may not well distinguish 
neoplasms according to grade.   
 
In all LMS samples we found a significant over-expression of alpha-SMA, thus 
confirming both its role as marker of LMS phenotype, as well as providing 
indirect evidence for the reliability of analyzed samples.  
Also, the expression of myo-miRNAs (miR-1, miR-133a-3p and miR-133b) was 
significantly higher in LMS compared to MFS and UPS, their expression being 
consistent and directly correlated in all LMS samples.  
In particular, miR-1 and miR-133a have been demonstrated to have a role in 
repressing isoforms of genes that are normally not expressed in muscle, with 
targets of miR-1 and miR-133a being up-regulated in rhabdomyosarcomas, thus 
suggesting a causative role for these miRNAs in the development of 
rhabdomyosarcomas [Rao PK et al, FASEB J. 2010].  
It was shown that miR-133 is involved in muscle development by targeting 
several genes, and has also been identified as a key factor in cancer development 
[Yu H et al, Curr Drug Targets. 2014]. 
 
Moreover, this study provided some insights on the role of miRNAs in MET. In 
our samples indeed an inverse correlation between myo-miRNAs and Slug was 
found, consistently across all myo-miRNAs.  
It is known that miR-1 targets Slug, and this way it is suggested to inhibit EMT 
[Liu YN, et al. Oncogene. 2013]. To the best of our knowledge, miR-133a and 
miR-133b have not been correlated with Slug-dependent inhibition of EMT yet, 





We demonstrated a high expression of such myo-miRNAs in all LMS samples, 
and demonstrated a positive correlation between the three of them, suggesting a 
cooperative role in the genesis of LMS.  
The consistent expression of myo-miRNAs in all LMS samples may serve both as 
a diagnostic aid for difficult and/or controversial cases, as well as possible  future 
development of miRNA-based gene therapy.   
 
EMT markers ZEB-1 and ZEB-2 were differentially expressed in LMS and UPS 
compared to MFS and, globally, both these histological types had worse overall 
survival compared to MFS.  
Interestingly, ZEB-1 and ZEB-2 were highly expressed in HG compared to LG 
LMS, and this could reflect the role of ZEB-1 and ZEB-2 as key molecules for 
MET. 
N-cadherin expression was found to be significantly higher in LMS compared to 
MFS and UPS, and Periostin expression was significantly higher in LMS and UPS 
compared to MFS.  
Interestingly, the expression of ZEB-1, ZEB-2 and Periostin was correlated with 
worse survival in a univariate analysis, suggesting they could be used as 
prognostic markers.  
Indeed, besides known prognostic factors such as grade, or histological subtypes – 
in our samples UPS had worse overall survival, confirming their undifferentiated, 
high grade morphology- the only markers significantly associated with prognosis 
prediction in our study were ZEB-1 and Periostin. 
 
In this study we did not find any correlation between EMT markers or miRNAs 
and PFS, yet this result must be taken with caution given the low overall number 
of samples and relatively high number of censored data for PFS.  
 
Also, we found an inverse correlation, with a trend to statistical significance, 
between the expression of ZEB-1 and miR-200b.  This may reflect the mutual  
role of miR-200 family member and ZEB-1 in driving sarcoma cells to a more 
epithelial-like state, confirming a recently published finding [Somarelli JA et al. 





In light of the findings from this study, we have planned to proceed with 
validation of such results in a larger sample and to provide a correlation with 
immunoistochemical staining.  
It could also be worthwhile to study circulating levels of periostin. In fact, 
periostin circulating levels have been demonstrated to be associated with distant 
metastases and poor prognosis in patients with colorectal cancer [Ben QW et al.  
Int J Oncol. 2009]. It could be therefore interesting to study whether circulating 
periostin and N-cadherin may be correlated with outcomes and response to 





























Conclusions and perspectives 
 
STS are still a subset of neoplasms in which progress is difficult to achieve due to 
their rarity, heterogeneity and complexity. Some histological subtypes, even the 
ones that have higher prevalence such as LMS and UPS, have poor responses to 
chemotherapy and survival.  
Notwithstanding clear selection biases, our clinical, real-world data confirm that 
there is a benefit for patients that have been treated for advanced disease 
compared to those not receiving active treatment. Yet, the high rate of toxicity 
should prompt the search for newer, possibly more active and less toxic regimens.  
Our data also confirm the prognostic role of some clinical factors; specifically, the 
presence of extra-pulmonary metastatic sites, anemia, lymphopenia and elevated 
LDH were found to be correlated with worse survival. 
 
The analysis on tumor samples highlighted that a “myo-miRNA” signature  may 
serve as potential confirmatory markers in samples with difficult/controversial 
histological findings.  
Moreover, some biomarkers linked to the mesenchymal phenotype, and in 
particular ZEB-1 and periostin were associated with worse prognosis.   
These data suggest the hypothesis that these biomarkers could help clinical 
decision when indication to treatment is not clear.  
Future work will include immunohistochemistry staining of these EMT 
biomarkers to confirm whether transcripts expression is correlated to protein 
levels, to possibly be used to help diagnostics and clinical decision.  
Also, evaluation of Periostin circulating levels may be studied for their possible 
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